Bioavailability is the proportion of an administered compound that reaches systemic circulation in a form capable of biological activity. For cannabinoids, which are fat-soluble compounds poorly absorbed in aqueous environments, bioavailability is not fixed — it varies substantially based on how the compound is delivered. The carrier medium, the administration route, and the presence or absence of lipid compounds all affect how much of what is taken actually reaches the sites where it can act. That variability is documented, measurable, and pharmacologically significant. It is also something that preparation method directly controls.

Why Cannabinoids Are Poorly Bioavailable in Water

Cannabinoids are lipophilic — they are chemically attracted to fats and oils and repelled by water. In aqueous solution, they aggregate into droplets, are poorly absorbed through intestinal walls, and undergo extensive first-pass metabolism in the liver before reaching systemic circulation. Oral bioavailability of cannabinoids in aqueous or unformulated preparations is consistently reported in the range of 6–19% in human pharmacokinetic studies — meaning that the majority of what is consumed never reaches the bloodstream in active form.

This low baseline bioavailability is not a minor detail. It is the reason that food-grade and pharmaceutical formulation research has invested heavily in lipid-based delivery systems for cannabinoids and other fat-soluble bioactive compounds. The question is not whether lipid carriers improve bioavailability — that is established. The question is which lipid carriers improve it most, through what mechanisms, and what practical implications that has for preparation choice.

What Lipid Carriers Actually Do

Lipid-based drug delivery systems improve bioavailability of fat-soluble compounds through several converging mechanisms. When fat-soluble compounds are dissolved in a lipid carrier and consumed, the body's fat-digestion machinery processes them alongside the carrier. Bile salts emulsify the lipid preparation in the small intestine, forming mixed micelles — tiny lipid structures that carry fat-soluble compounds directly to intestinal wall cells for absorption. Compounds in solution within a lipid carrier are incorporated into these micelles far more efficiently than compounds presented in aqueous suspension.

Long-chain triglycerides — the primary lipid class in olive oil — stimulate robust bile acid secretion, which drives efficient micelle formation and absorption. A 2019 pharmacokinetic study by Zgair and colleagues, examining cannabidiol bioavailability across different lipid formulations, found that long-chain fatty acid preparations produced significantly higher plasma cannabinoid levels than medium-chain triglyceride preparations at equivalent doses, and dramatically higher levels than aqueous administration. The mechanism is bile acid secretion — long-chain triglycerides trigger more of it, and more bile acids mean more efficient micelle formation and better fat-soluble compound absorption.

Olive oil is rich in long-chain monounsaturated fatty acids — primarily oleic acid — and produces a strong bile acid response. This is the pharmacological basis for using EVOO as a carrier for fat-soluble cannabinoids in a topical preparation. It is not a preference for tradition or flavour. It is a preparation chemistry decision grounded in documented absorption physiology.

The Polyphenol Question — When the Carrier Contributes

Extra virgin olive oil is not simply a lipid carrier. It contains oleocanthal — a phenolic compound with documented COX-1 and COX-2 inhibitory activity first characterised by Beauchamp and colleagues in a 2005 Nature paper. It contains oleuropein, hydroxytyrosol, and other polyphenols with documented antioxidant activity. It contains squalene and phytosterols with their own preliminary research profiles. The polyphenol content varies significantly with olive variety, growing conditions, and processing method — heat, light, and oxidation all degrade polyphenol content — which is why cold-pressed, high-quality EVOO has a markedly different chemical profile from refined olive oil.

This raises a question that has not been formally studied but is grounded in documented mechanism: whether EVOO's polyphenol content contributes biological activity alongside its role as a lipid carrier. For topical application — the context in which JP Hemp uses EVOO as a carrier — the skin has its own lipid uptake pathways, and EVOO's polyphenols have documented skin-level anti-inflammatory properties in preclinical models. Whether those polyphenols contribute meaningfully in a topically applied cannabinoid preparation is an open research question. What is established is that they are present, that they have individual evidence at the same biological targets relevant to the preparation's purpose, and that a refined lipid carrier would not provide them.

The argument for EVOO as a carrier is therefore two-layered. At the primary level, it is a lipid carrier with a long-chain fatty acid profile that supports efficient lipid absorption pathways. At the secondary level, it brings its own phytochemistry — with its own documented biological activity — rather than being a pharmacologically inert delivery vehicle. Whether that secondary layer produces meaningful additive effect in practice has not been established by controlled research. It is, however, a pharmacologically coherent hypothesis grounded in documented individual compound activity — the same standard applied to whole-plant cannabinoid preparations throughout this section of the archive.

Sublingual Administration and Carrier Interaction

Sublingual administration — holding a preparation under the tongue — works through a different absorption pathway than gastrointestinal absorption, and carrier interaction matters here too. The sublingual mucosa is richly vascularised and relatively permeable to lipid-soluble compounds. Absorption through the sublingual route bypasses first-pass liver metabolism, which is the primary reason sublingual bioavailability for cannabinoids is consistently reported as higher than oral bioavailability — typically in the range of 13–35% in pharmacokinetic studies, compared to 6–19% orally.

Alcohol — the carrier in a slow-maceration tincture — supports sublingual absorption in a specific way. It acts as a penetration enhancer at the mucosal surface, temporarily increasing membrane permeability and facilitating faster uptake of dissolved compounds. This is not a side effect of the alcohol content — it is a documented mucosal pharmacology property of ethanol that has been studied in transdermal and sublingual drug delivery research. A cannabinoid dissolved in alcohol and held sublingually benefits from both the high mucosal vascularisation and the penetration-enhancing property of the solvent. This combination contributes to the faster onset and higher bioavailability commonly reported with alcohol-based sublingual preparations compared to oil-based sublingual preparations at equivalent concentrations.

What This Means in Practice

The practical implications are specific. For sublingual use, an alcohol-based tincture provides faster onset and higher mucosal bioavailability than an oil-based preparation. For oral use, a lipid-based preparation — consumed with or as part of a meal containing fat — provides substantially higher bioavailability than an aqueous preparation or an alcohol preparation swallowed directly. For topical use, a quality EVOO carrier provides a lipid medium that supports skin absorption of fat-soluble cannabinoids, with polyphenols present alongside that do not compromise and may complement the preparation's purpose.

These are not claims that any specific preparation produces specific clinical outcomes. They are documented pharmacokinetic principles applied to preparation choice — the same reasoning that pharmaceutical formulators apply when designing lipid-based drug delivery systems for poorly water-soluble compounds. The preparation methods used in traditional botanical medicine arrived at these conclusions empirically. The pharmacokinetics provide the mechanism. Both are pointing in the same direction, and that convergence is worth understanding when making informed choices about how a preparation is made and how it is used.